Objective To update the 2001 American Academy of Neurology (AAN) guideline on mild cognitive impairment (MCI).
Glossary AAN = American Academy of Neurology; AD = Alzheimer disease; aMCI = amnestic mild cognitive impairment; CI = confidence interval; CIND = cognitively impaired, no dementia; FDA = Food and Drug Administration; IADL = instrumental activities of daily living; MCI = mild cognitive impairment; RR = relative risk.
Mild cognitive impairment (MCI) is a condition in which individuals demonstrate cognitive impairment with minimal impairment of instrumental activities of daily living (IADL). [1] [2] [3] Although MCI can be the first cognitive expression of Alzheimer disease (AD), it can also be secondary to other disease processes (i.e., other neurologic, neurodegenerative, systemic, or psychiatric disorders). 4 The term amnestic MCI (aMCI) describes a syndrome in which memory dysfunction predominates; in nonamnestic MCI, impairment of other cognitive features (e.g., language, visuospatial, executive) is more prominent. 2 This practice guideline updates a 2001 American Academy of Neurology (AAN) practice parameter with recommendations concerning the diagnosis and treatment of MCI. 5 The guideline focuses on presumed idiopathic or neurodegenerative MCI-particularly relating to AD-rather than mild cognitive changes relating to potentially reversible causes (e.g., metabolic, vascular, systemic, or psychiatric disorders) or Parkinson disease-MCI or vascular cognitive impairment, as these may have different epidemiologic and treatment spectra than AD. This article summarizes the guideline findings, conclusions, and recommendations. The full text of the guideline, including appendices e-1 through e-8, is available as supplemental data (links.lww. com/WNL/A125), as are tables e-1 through e-3 (links.lww.com/ WNL/A34) and references e1-e50 (links.lww.com/WNL/A50).
The guideline addresses 4 questions:
1. What is the prevalence of MCI in the general population? 2. What is the prognosis for patients diagnosed with MCI for progression to a diagnosis of dementia, and how does this compare with an age-matched general population? 3. What pharmacologic treatments are effective for patients diagnosed with MCI? 4. What nonpharmacologic treatments are effective for patients diagnosed with MCI?
This guideline does not review the rapidly evolving field of biomarker research in MCI; the guideline panel determined that this should be the subject of a future guideline or systematic review. In addition, the potential psychological distress of a diagnosis of MCI (which has been discussed in the literature) was not one of the questions reviewed by the expert panel for this guideline. 6 
Description of the analytic process
This practice guideline principally follows the methodologies described in the 2004 edition of the AAN's guideline development process manual. 7 Conclusions and recommendations were developed in accordance with the process outlined in the 2011 guideline development process manual, as amended to include the updated scheme for classifying therapeutic articles. 8 The complete guideline provides a description of the exact methodology followed, including the processes of convening the author panel, performing the literature search, and reviewing the evidence. In accordance with the 2011 guideline manual, recommendations were based not only on the evidence in the systematic review, but also on strong related evidence, established principles of care, and inferences. The level of obligation for each recommendation was based on the strength of these premises and the risk-benefit ratio of following the recommendation, with adjustments based on importance of outcomes, variation in patient preferences, feasibility/availability, and patient costs. Consensus was determined by a modified Delphi voting process in accordance with prespecified rules. 8 The panelists noted that various definitions of MCI and of related terms, such as cognitively impaired, no dementia (CIND), were used in the reviewed literature. Variation was based on different ascertainment methods, different neuropsychological measures, different measure thresholds, and requirements for different cognitive deficits. There was also variation in the use of aMCI and nonamnestic MCI in these studies. To address these discrepancies, the panelists reflected the specific definition used for a study where feasible in the evidence synthesis tables and guideline text, and provided specific comments on the potential effect of differing definitions.
Analysis of evidence
What is the prevalence of MCI in the general population?
Background
Various definitions of MCI have been used over time, reflecting an evolution of thought from primarily focusing on amnesia to including other cognitive deficits. Because memory deficits are the clinical hallmark of AD, some groups used criteria for MCI that required the presence of memory deficits in isolation (e.g., aMCI), 3, 9, 10 and others included a broader definition that included either single-domain
Supplemental Data
Full text of guideline at: NPub.org/4evlhy nonamnestic deficits or deficits in multiple cognitive domains, either with memory impairment (multidomain aMCI) or without (multidomain nonamnestic MCI). 1, 2, 11 The definition of MCI is also affected by the psychometric properties of, and norms for, the tests used to identify thresholds between normal aging and MCI. were identified. Eight of the Class I studies showed that a lower education level was significantly associated with a higher prevalence of MCI. 9, 10, 14, 18, 21, 24, 27, 28 Two of the Class I studies indicated that male sex was associated with the presence of MCI 13, 24 but other studies found similar baseline prevalence in men and women. 14, 15, 27 A random-effects meta-analysis using Class I and II studies confirmed an increased prevalence with cohort age. The allstudies estimate for individuals aged 60-64 years was 6 
Conclusions
MCI is common in older populations, and its prevalence increases with age (high confidence, multiple Class I and Class II studies, consistent meta-analysis) and lower educational level (high confidence, multiple Class I studies).
What is the prognosis for patients diagnosed with MCI for progression to a diagnosis of dementia, and how does this compare with an age-matched general population?
Analysis
Nine Class I studies evaluated prognosis for individuals with MCI, 9,13,19,23,27,e2,e4-e7 all showing an increased risk of progression to dementia when participants with MCI were compared with age-matched participants without MCI. A random-effects meta-analysis demonstrated that the cumulative incidence for the development of dementia in individuals with MCI/CIND older than age 65 followed for 2 years was 14.9% (95% CI 11.6%-19.1%, I 2 = 0). In those with MCI/CIND vs age-matched participants at 2-5 years after, the relative risk (RR) of dementia (all types) was 3.3 (95% CI 2.5-4.5, I 2 = 4.9); the RR of the diagnosis of AD was 3.0 (95% CI 2.1-4.8, I 2 = 17.3).
Reversion to normal cognition in individuals with MCI
Four Class I studies 9,19,23,e5 showed reversion to normal cognition on follow-up in 14.4%, 19 33.3%, 9 19%, 23 and 38% e5 of participants with MCI. However, 2 studies documented increased rates of ultimate conversion to dementia in participants with MCI who reverted to normal cognition, suggesting that individuals who revert remain at a higher risk of progression back to MCI or dementia than individuals who have never received an MCI diagnosis (in these studies, 65% e5 and 55% ultimately converted to dementia e8 ).
Conclusions
Persons with MCI are at higher risk of progressing to dementia than age-matched controls (high confidence, multiple concordant Class I studies, meta-analysis and 4 Class III studies e25-e28 investigated the use of various cognitive interventions. Table 2 describes the available studies and conclusions for each nonpharmacologic intervention; details are provided in the full-length guideline (links.lww.com/WNL/A125).
Putting the evidence into clinical context
Care for persons with cognitive impairment meeting various MCI criteria continues to evolve, with the area of biomarker research changing particularly rapidly. Even in the context of an evolving field, clinicians can provide high-quality care focusing on counseling, treatment, and comorbidity management. Where clinicians are not proficient in caring for the cognitive or behavioral/psychiatric needs of persons with MCI, referral to appropriate specialists is an important part of the treatment paradigm in line with the following recommendations.
Practice recommendations
Section A: Recommendations for assessing for MCI Recommendation A1
Rationale
Appropriate diagnosis of MCI is important because MCI becomes increasingly common as individuals age and is associated with an increased risk of progression to dementia, suggesting that this condition reflects a pathologic disease state rather than normal cognitive aging. Appropriate diagnosis of MCI is important in order to assess for reversible causes of cognitive impairment, to help patients and families understand the cause of their cognitive concerns, and to discuss the prognostic possibilities with the provider so they can plan accordingly, although sharing the diagnosis must be balanced with the potential harm of anxieties from diagnosing a patient with a condition that may not progress. Ascribing cognitive symptoms to normal aging without an assessment for MCI may ). Study CIs could not exclude an important effect and the ADAS-Cog change was statistically significant but not clinically meaningful.
Galantamine
2 Class II studies (Winblad 2008, e13 both studies reported in 1 article)
In patients with MCI, galantamine use over 24 months is probably ineffective for reducing progression to dementia (moderate confidence in the evidence based on 2 Class II studies). In patients with MCI, use of vitamin E 2,000 IU daily is possibly ineffective for reducing progression to AD (low confidence in the evidence based on a single Class II study).
Vitamin E + vitamin C 1 Class III study (Naeini 2014 e21 )
In patients with MCI, combined use of oral vitamin E 300 mg and C 400 mg daily over 12 months is of uncertain efficacy (very low confidence in the evidence based on 1 Class III study).
Abbreviations: AD = Alzheimer disease; ADAS-Cog = Alzheimer's Disease Assessment Scale-cognitive subscale; aMCI = amnestic mild cognitive impairment; CI = confidence interval. References cited here can be found in the e-references (links.lww.com/WNL/A50) for the guideline summary article. a Rofecoxib was removed from the market worldwide in September 2004. There are no data on whether other anti-inflammatory medications are effective or harmful in patients with MCI. b It is unclear from this study whether this is effect is sustained beyond 20 weeks.
result in failure to assess for reversible causes of cognitive impairment or to provide patients and families with an accurate diagnosis that may affect life choices, or both. Although subjective cognitive complaints alone are insufficient to diagnose MCI, e29 such complaints from either patients or their close contacts are core to most major MCI diagnostic criteria, as they may reflect a change in cognitive function. 
Recommendation
For patients for whom the patient or a close contact voices concern about memory or impaired cognition, clinicians should assess for MCI and not assume the concerns are related to normal aging (Level B).
Recommendation A2

Rationale
In the United States, the Medicare Annual Wellness Visit requires an assessment to detect cognitive impairment. Subjective cognitive complaints alone can result in overdiagnosis or underdiagnosis of MCI and thus are insufficient to screen for MCI.
e29 Clinicians assessing for cognitive impairment should use a brief, validated cognitive assessment instrument in addition to eliciting patient and informant history regarding cognitive concerns.
Recommendation
When performing a Medicare Annual Wellness Visit, clinicians should not rely on historical report of subjective memory concerns alone when assessing for cognitive impairment (Level B).
Recommendation A3
Rationale
When screening or assessing for MCI, validated assessment tools should be used. Various instruments have acceptable diagnostic accuracy for detecting MCI, with no instrument being superior to another.
e32 Because brief cognitive assessment instruments are usually calibrated to maximize sensitivity rather than specificity, patients who test positive for MCI should then have further assessment (e.g., more indepth cognitive testing, such as neuropsychological testing with interpretation based on appropriate normative data) to formally assess for this diagnosis. Diagnosis of MCI is based ultimately on a clinical evaluation determining cognitive function and functional status and not solely on a specific test score.
Recommendation
For patients for whom screening or assessing for MCI is appropriate, clinicians should use validated assessment tools to assess for cognitive impairment (Level B). For patients who test positive for MCI, clinicians should perform a more formal clinical assessment for diagnosis of MCI (Level B).
Recommendation A4
Rationale
In the presence of cognitive impairment, clinicians need to distinguish between a diagnosis of MCI and one of dementia, although the boundary is not always clear. Diagnosing dementia prematurely can lead to negative consequences for patients and families. Only a proportion of patients with MCI will proceed to dementia. In patients with cognitive ] showing improvement on the MMSE but with some limitations, and 1 Class III study [Lam 2015 e28 ] showing no differences when all patients with MCI are considered, but with improvements in the integrated cognitive-physical training groups when considering the ADASCog, fluency, and recall in patients with single-domain MCI and fluency in patients with multidomain MCI).
Abbreviations: ADAS-Cog = Alzheimer's Disease Assessment Scale-cognitive subscale; MMSE = Mini-Mental State Examination. References cited here can be found in the e-references (links.lww.com/WNL/A50) for the guideline summary article.
impairment, clinicians must carefully assess for evidence of functional impairment limiting independence in daily activities (e.g., by taking a careful history from the patient and a close contact), a requirement for all dementia diagnoses, to help distinguish between MCI and dementia. With a specific inquiry about functional impairment, clinicians may also identify dementia in patients when patients and family are less forthcoming about functional problems.
Recommendation
For patients with MCI, clinicians should assess for the presence of functional impairment related to cognition before giving a diagnosis of dementia (Level B).
Recommendation A5
Rationale
Diagnoses of MCI and dementia have important implications for patients and families. Appropriate diagnosis is important for informing evaluation for underlying causes, counseling on longterm prognosis, and recommending therapeutic strategies. Clinicians in many disciplines can have experience in caring for individuals with cognitive impairment, including family practice, geriatrics, internal medicine, neurology, psychiatry, and psychology. When clinicians without experience in cognitive impairment identify patients for whom there is a concern of MCI, they should refer these patients to a specialist with experience in cognition for further evaluation.
Recommendation
For patients suspected to have MCI, clinicians who lack the necessary experience should refer these patients to a specialist with experience in cognition (Level B).
Recommendation A6
Rationale
Although MCI is a high-risk state for progression to dementia, some patients with MCI remain stable and some improve. Some cases of MCI are associated with reversible causes of cognitive impairment, including medication side effects, sleep apnea, depression, and other medical conditions. e33 Patients with MCI should undergo a medical evaluation for MCI risk factors that may be treatable.
Recommendation
For patients diagnosed with MCI, clinicians should perform a medical evaluation for MCI risk factors that are potentially modifiable (Level B).
Recommendation A7
Rationale
Because patients with MCI can improve, remain stable, or progress cognitively, identifying biomarkers that can stratify risk is expected to be particularly important for prognosis. The use of biomarkers in patients with MCI is a rapidly evolving field, e34-e36 but to date, there are no biomarkers clearly shown to predict progression in patients with MCI. 
Recommendation A7a
For patients and families asking about biomarkers in MCI, clinicians should counsel that there are no accepted biomarkers available at this time (Level B).
Recommendation A7b
For interested patients, clinicians may discuss the option of biomarker research or refer patients, or both, if feasible, to centers or organizations that can connect patients to this research (e.g., subspecialty centers, Trial Match, ClinicalTrials.gov) (Level C).
Recommendation A8
Rationale
Because patients with MCI can improve, remain stable, or progress cognitively over time, patients must be monitored serially for changes in status that could change diagnosis and thus management approach (e.g., treatment, counseling). Although MCI has no approved pharmacologic management, there are US Food and Drug Administration (FDA)-approved agents for treatment of Alzheimer dementia, e38-e42 further emphasizing the importance of assessing for a change in cognitive status over time.
Recommendation
For patients diagnosed with MCI, clinicians should perform serial assessments over time to monitor for changes in cognitive status (Level B).
Section B: Recommendations for management of MCI Recommendation B1
Rationale Some patients with MCI improve or remain stable rather than progress. In addition, some cases of MCI are associated with reversible causes of cognitive impairment, including medication side effects, general medical conditions, sleep disturbance, and depression.
e33 Because these risk factors are treatable and have implications of their own, weaning patients from use of cognitively impairing medications where feasible and treating risk factors that may contribute to cognitive impairment should be the first steps in managing MCI, particularly because symptomatic treatment options are limited for impaired cognition.
Recommendation
For patients diagnosed with MCI, clinicians should wean patients from medications that can contribute to cognitive impairment (where feasible and medically appropriate) and treat modifiable risk factors that may be contributing (Level B).
There are no FDA-approved medications for the treatment of MCI. Moreover, there are no high-quality, long-term studies identifying pharmacologic or dietary agents that either improve cognition or delay progression in patients with MCI.
For patients diagnosed with MCI, clinicians should counsel the patients and families that there are no pharmacologic or dietary agents currently shown to have symptomatic cognitive benefit in MCI and that no medications are FDA-approved for this purpose (Level B).
Recommendation B3
Rationale
Studies of cholinesterase inhibitors showed no benefit on cognitive outcomes or reduction in progression from MCI to dementia, although some studies could not exclude an important effect. In addition to lacking efficacy, side effects of cholinesterase inhibitors are common, including gastrointestinal symptoms and cardiac concerns. 
Recommendation B3a
For patients diagnosed with MCI, clinicians may choose not to offer cholinesterase inhibitors (Level B).
Recommendation B3b
If clinicians choose to offer cholinesterase inhibitors, they must first discuss with patients the fact that this is an off-label prescription not currently backed by empirical evidence (Level A).
Recommendation B4
Rationale
Clinical trials provide an opportunity for interested patients to participate in identifying or testing new treatment options, which is of particular importance when no pharmacologic options are available.
Recommendation
For patients diagnosed with MCI who are interested in pharmacologic treatment, clinicians may inform these patients of centers or organizations that can connect patients to clinical trials (e.g., subspecialty centers, Trial Match, ClinicalTrials.gov) (Level C).
Recommendation B5
Rationale
Although long-term studies are unavailable, 6-month studies suggest a possible benefit of twice-weekly exercise for cognition in MCI. Exercise also has general health benefits and generally limited risk.
Recommendation
For patients diagnosed with MCI, clinicians should recommend regular exercise (twice/week) as part of an overall approach to management (Level B).
Recommendation B6
Rationale
Because the concept of MCI may be poorly understood or distressing to patients and families, it is important to educate patients and families regarding the diagnosis of MCI and how it may progress to dementia but also how individuals with MCI can remain stable or improve. Because MCI may progress to dementia, and particularly because of the lack of effective pharmacologic therapy or any proven methods to reduce the risk of progression of MCI to dementia, it is particularly important to educate patients with MCI regarding their diagnosis and prognosis at the MCI stage while they can still understand the discussion and participate in planning, even though they may or may not progress. Because of the possibility of progression to a dementia state where patients may no longer be able to participate in decision making, patients with MCI should be encouraged to participate in long-term planning, including topics such as advance directives, living wills, power of attorney designations, and finances, which are important irrespective of progression.
Recommendation
For patients diagnosed with MCI, clinicians should discuss diagnosis and uncertainties regarding prognosis. Clinicians should counsel patients and families to discuss long-term planning topics such as advance directives, driving safety, finances, and estate planning (Level B).
Recommendation B7
Rationale
Although there are no treatments for cognitive symptoms in MCI, clinicians need to evaluate for and treat other symptoms that can contribute to quality of life in MCI. Behavioral/psychiatric symptoms are common in MCI e44-e46 and may be associated with greater functional impairment e47 and an increased risk of progression from MCI to dementia.
e48,e49
Recommendation
Clinicians should assess for behavioral and neuropsychiatric symptoms in MCI and treat with both pharmacologic and nonpharmacologic approaches when indicated (Level B).
In patients with MCI, cognitive interventions may be beneficial in improving measures of cognitive function. It is good practice to offer nonmedication approaches to care.
In patients with MCI, clinicians may recommend cognitive interventions (Level C).
Suggestions for future research
The guideline panel recommends (1) the use of consistent diagnostic criteria for MCI and dementia in clinical trials, to improve the ability to apply and combine results; (2) the inclusion of patient cohorts with specific biomarker data in treatment studies targeted at specific pathologies (e.g., MCI due to AD); (3) the use of outcome measures that are direct measures of clinically meaningful patient outcomes (i.e., development of dementia, reduction of ability to undertake activities of daily living or IADL, patient or caregiver [or both] quality of life measures) or surrogate markers that have previously been shown to have a strong correlation with such measures; (4) standardized reporting of trial design in publications using CONSORT criteria e50 ; (5) study of MCI thought to be secondary to AD and MCI related to other pathologies (e.g., vascular MCI, MCI related to Lewy body pathology); and (6) further study of early lifestyle and comorbidity modifications and the effects of such changes on the progression of MCI to different dementia subtypes.
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